Media Coverage
“Correlates and Endpoints - Detailed results from the RV144 HIV vaccine trial”
BioCentury >
“Profectus Biosciences Preclinical Results pDNA, rVSV”
BioCentury Part II>
“Viral Vaccine Co. Profectus Takes $5M More From Cross Atlantic”
Dow Jones VentureWire Lifescience>
“Another Biotech Firm Chooses Westchester”
Westchester County Business Journal>
“Profectus Biosciences lands $5M round of venture capital”
Baltimore Business Journal >
“Morrison, Trista. “NewCo News: Profectus Seeks a Bio Niche Hitting HIV from all Angles”
BioWorld Today. vol 19 no 40. February 28, 2008.>
"Homegrown biotech eyes federal deals.”
Business Journal >
"Andersen Was Never This Rewarding.”
Business Week >
“Rosenwald, Michael. “Extreme makeover: Corporate heavyweights translate their talents into success in new sectors” Washington Post. Sept. 10, 2007. D1+. Print.>
“Top incubator companies honored”
Baltimore Business Journal >
“Gallo biotech lures former Andersen CEO”
Baltimore Business Journal >
“Gallo spinoff has new name, $2 million in venture capital ...”
Baltimore Business Journal >
“Profectus here to stay.”
MD Health Care May 2005 >
“Profectus BioSciences, Inc. commences operations”.
Spring 2005 Discovery Scientific Newsletter - IHV >
“Profectus Raises $3M Series A To Aid Viral Treatments”
Venturewire II >
|